Barclays PLC Rallybio Corp Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Rallybio Corp stock. As of the latest transaction made, Barclays PLC holds 15,390 shares of RLYB stock, worth $14,620. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,390

Previous 15,390 -0.0%

Holding current value

$14,620

Previous $18,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$1.09 - $1.45 $12,152 - $16,166	-11,149 Reduced 42.01%	15,390 $18,000
Q2 2024 Aug 14, 2024	SELL	$1.34 - $2.98 $14,044 - $31,233	-10,481 Reduced 28.31%	26,539 $36,000
Q1 2024 May 15, 2024	SELL	$1.25 - $2.4 $25,573 - $49,101	-20,459 Reduced 35.59%	37,020 $68,000
Q4 2023 Feb 15, 2024	BUY	$1.91 - $4.39 $98,032 - $225,321	51,326 Added 834.16%	57,479 $138,000
Q3 2023 Nov 07, 2023	BUY	$3.37 - $6.16 $168 - $308	50 Added 0.82%	6,153 $20,000
Q2 2023 Aug 03, 2023	SELL	$4.31 - $8.89 $14,972 - $30,883	-3,474 Reduced 36.27%	6,103 $35,000
Q1 2023 May 04, 2023	BUY	$4.37 - $8.75 $20,237 - $40,521	4,631 Added 93.63%	9,577 $54,000
Q4 2022 Feb 13, 2023	BUY	$4.67 - $14.86 $19,940 - $63,452	4,270 Added 631.66%	4,946 $33,000
Q3 2022 Nov 03, 2022	SELL	$7.54 - $14.56 $35,649 - $68,839	-4,728 Reduced 87.49%	676 $10,000
Q2 2022 Aug 12, 2022	SELL	$6.26 - $13.65 $13,396 - $29,211	-2,140 Reduced 28.37%	5,404 $41,000
Q1 2022 May 16, 2022	BUY	$6.91 - $15.04 $52,129 - $113,461	7,544 New	7,544 $52,000

Others Institutions Holding RLYB

# of Institutions

Shares Held

31.9M

Call Options Held

Put Options Held

View Full List

About Rallybio Corp

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $30.5M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

More about RLYB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account